Novavax, Inc. is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

Company profile
Ticker
NVAX
Exchange
Website
CEO
Stanley Erck
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne ...
SEC CIK
Corporate docs
Subsidiaries
Novavax AB ...
IRS number
222816046
NVAX stock data
News

Novavax's Covid-19 Vaccine Cleared For Use In New Zealanders Aged 12-17
18 Aug 22
Novavax Nuvaxovid COVID-19 Vaccine Granted Expanded Provisional Approval In New Zealand For Adolescents Aged 12 Through 17
18 Aug 22
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday
18 Aug 22
If You Invested $1,000 In Johnson & Johnson Stock At Its COVID-19 Pandemic Low, Here's How Much You'd Have Now
17 Aug 22
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
17 Aug 22
Press releases
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Adolescents Aged 12 Through 17
19 Aug 22
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17
18 Aug 22
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as a First and Second Booster for Adults
17 Aug 22
Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older
15 Aug 22
Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17
12 Aug 22
Analyst ratings and price targets
Current price
Average target
$139.00
Low target
$110.00
High target
$168.00
Cowen & Co.
Maintains
$110.00
Cantor Fitzgerald
Maintains
$168.00
Calendar
8 Aug 22
20 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.39B | 1.39B | 1.39B | 1.39B | 1.39B | 1.39B |
Cash burn (monthly) | 65.53M | 61.27M | 169.69M | 120.49M | 56.97M | 62M |
Cash used (since last report) | 110.41M | 103.23M | 285.91M | 203.01M | 95.99M | 104.46M |
Cash remaining | 1.28B | 1.28B | 1.1B | 1.18B | 1.29B | 1.28B |
Runway (months of cash) | 19.5 | 21.0 | 6.5 | 9.8 | 22.7 | 20.7 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Aug 22 | James Patrick Kelly | Common Stock | Payment of exercise | Dispose F | No | No | 42.88 | 1,144 | 49.05K | 1,223 |
16 Aug 22 | James Patrick Kelly | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,367 | 0 | 2,367 |
16 Aug 22 | James Patrick Kelly | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 2,367 | 0 | 4,733 |
25 Jun 22 | Trizzino John | Common Stock | Payment of exercise | Dispose F | No | No | 51.67 | 278 | 14.36K | 3,928 |
25 Jun 22 | Trizzino John | Common Stock | Option exercise | Acquire M | No | No | 0 | 833 | 0 | 4,206 |
25 Jun 22 | Trizzino John | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 833 | 0 | 833 |
25 Jun 22 | Herrmann John A III | Common Stock | Payment of exercise | Dispose F | No | No | 51.67 | 278 | 14.36K | 4,400 |
25 Jun 22 | Herrmann John A III | Common Stock | Option exercise | Acquire M | No | No | 0 | 833 | 0 | 4,678 |
25 Jun 22 | Herrmann John A III | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 833 | 0 | 833 |
17 Jun 22 | Douglas Richard | Common Stock | Option exercise | Acquire M | No | No | 0 | 700 | 0 | 34,150 |
Institutional ownership, Q2 2022
42.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 312 |
Opened positions | 54 |
Closed positions | 117 |
Increased positions | 90 |
Reduced positions | 97 |
13F shares | Current |
---|---|
Total value | 1.85B |
Total shares | 33.22M |
Total puts | 5.73M |
Total calls | 4.34M |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 7.35M | $378.06M |
BLK Blackrock | 4.26M | $219.01M |
STT State Street | 2.97M | $152.59M |
MS Morgan Stanley | 1.29M | $66.15M |
Coatue Management | 1.24M | $63.86M |
C Citigroup | 1.22M | $62.89M |
Geode Capital Management | 1.02M | $52.59M |
Millennium Management | 869.41K | $44.71M |
Voloridge Investment Management | 848.14K | $43.62M |
Citadel Advisors | 689.16K | $35.44M |
Financial report summary
?Competition
Geovax Labs • Mymetics • Dynavax Technologies • Inovio Pharmaceuticals • Oragenics • ImmunityBio • Altimmune • Ocugen • Tonix Pharmaceuticals Holding • Selecta BiosciencesRisks
- The emergence and transmissibility of variants of the SARS-CoV-2 virus may affect market acceptance or sales of NVX-CoV2373, and our strategy to develop versions of our COVID-19 vaccine to protect against certain variants may not be successful.
Management Discussion
- Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
- Any statements in the discussion below and elsewhere in this Quarterly Report on Form 10-Q (this “Quarterly Report”) about expectations, beliefs, plans, objectives, assumptions, or future events or performance of Novavax, Inc. (“Novavax,” and together with its wholly owned subsidiaries, the “Company,” “we,” or “us”) are not historical facts and are forward-looking statements. Such forward-looking statements include, without limitation, statements about our capabilities, goals, expectations regarding future revenue and expense levels, and capital raising activities; our operating plans and prospects; potential market sizes and demand for our product candidates; the efficacy, safety, and intended utilization of our product candidates; the development of our clinical-stage product candidates and our recombinant vaccine and adjuvant technologies; the development of our preclinical product candidates; our expectations related to enrollment in our clinical trials; the conduct, timing, and potential results from clinical trials and other preclinical studies; plans for and potential timing of regulatory filings; our expectation of manufacturing capacity, timing, production, distribution, and delivery for our coronavirus vaccine candidate (“NVX-CoV2373”) by us and our partners; our estimate of the number of individuals who may potentially be reached by NVX-CoV2373; our expectations with respect to the anticipated ongoing development and commercialization or licensure of NVX-CoV2373 and our seasonal quadrivalent influenza vaccine, previously known as NanoFlu; the expected timing, content, and outcomes of regulatory actions; funding from the U.S. government partnership formerly known as Operation Warp Speed (“OWS”), the U.S. Department of Defense (“DoD”), and the Coalition for Epidemic Preparedness Innovations (“CEPI”), and payments from the Bill & Melinda Gates Foundation (“BMGF”); funding under our advance purchase agreements and supply agreements and amendments to, or termination of, any such agreement; our available cash resources and usage and the availability of financing generally; plans regarding partnering activities and business development initiatives; and other matters referenced herein. Generally, forward-looking statements can be identified through the use of words or phrases such as “believe,” “may,” “could,” “will,” “would,” “possible,” “can,” “estimate,” “continue,” “ongoing,” “consider,” “anticipate,” “intend,” “seek,” “plan,” “project,” “expect,” “should,” “would,” “aim,” or “assume,” the negative of these terms, or other comparable terminology, although not all forward-looking statements contain these words.
- Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs and expectations about the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements involve estimates, assumptions, risks, and uncertainties that could cause actual results or outcomes to differ materially from those expressed or implied in any forward-looking statements, and, therefore, you should not place considerable reliance on any such forward-looking statements. Such risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities, such as the U.S. Food and Drug Administration (“FDA”), World Health Organization (“WHO”), United Kingdom (“UK”) Medicines and Healthcare Products Regulatory Agency (“MHRA”), the European Medicines Agency (“EMA”), the Republic of Korea’s Ministry of Food and Drug Safety (“MFDS”), or Japan’s Ministry of Health, Labour and Welfare (“MHLW”); unanticipated challenges or delays in conducting clinical trials; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, constraints on the ability of Novavax to pursue planned regulatory pathways, alone or with partners, in multiple jurisdictions simultaneously, leading to staggering of regulatory filings, and potential regulatory actions; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and other risks and uncertainties identified in Part I, Item 1A “Risk Factors” of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which may be detailed and modified or updated in other documents filed with the United States Securities and Exchange Commission (“SEC”) from time to time, and are available at www.sec.gov and at www.novavax.com. You are encouraged to read these filings as they are made.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
adapted, adapting, Amy, anniversary, answer, appoint, appointment, artwork, batch, Blackburn, campaign, counsel, deducting, description, deviation, EC, Energy, exhibit, expiry, foregoing, hearing, Hummingbird, idle, inclusive, IRC, Ireland, JCVI, labor, language, leave, momentum, mRNA, nonrefundable, obsolescence, Omicron, opinion, opposition, prefilled, provision, renegotiate, reply, slower, Snyder, syringe, Taiwan, underway, unmarketable, write
Removed:
ASC, assessment, biological, build, case, confirmed, Controller, decision, dosing, endpoint, EUL, expedient, extended, flexibility, forward, long, month, national, path, pathway, practical, proposed, protection, rapid, reactogenicity, recently, relevant, requiring, showing, successfully, terminated
Financial reports
Current reports
8-K
Novavax Reports Second Quarter 2022 Financial Results and Operational Highlights
8 Aug 22
8-K
Entry into a Material Definitive Agreement
11 Jul 22
8-K
Departure of Directors or Certain Officers
21 Jun 22
8-K
Novavax Reports First Quarter 2022 Financial Results and Operational Highlights
10 May 22
8-K
Regulation FD Disclosure
20 Apr 22
8-K
Departure of Directors or Certain Officers
7 Mar 22
8-K
Novavax Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
1 Mar 22
8-K
Regulation FD Disclosure
10 Feb 22
8-K
Entry into a Material Definitive Agreement
7 Feb 22
8-K
Regulation FD Disclosure
10 Jan 22
Registration and prospectus
S-8
Registration of securities for employees
8 Aug 22
S-8
Registration of securities for employees
5 Aug 21
424B5
Prospectus supplement for primary offering
15 Jun 21
424B5
Prospectus supplement for primary offering
22 Jan 21
424B5
Prospectus supplement for primary offering
10 Nov 20
424B5
Prospectus supplement for primary offering
10 Nov 20
424B7
Prospectus with selling stockholder info
10 Aug 20
S-8
Registration of securities for employees
10 Aug 20
424B5
Prospectus supplement for primary offering
18 May 20
S-3ASR
Automatic shelf registration
11 Mar 20
Proxies
DEFA14A
Additional proxy soliciting materials
3 May 22
DEFA14A
Additional proxy soliciting materials
27 May 21
DEFA14A
Additional proxy soliciting materials
24 May 21
DEFA14A
Additional proxy soliciting materials
3 May 21
DEF 14A
Definitive proxy
3 May 21
PRE 14A
Preliminary proxy
21 Apr 21
DEFA14A
Additional proxy soliciting materials
18 Jun 20
DEFA14A
Additional proxy soliciting materials
12 May 20
Other
EFFECT
Notice of effectiveness
10 Jan 20
CORRESP
Correspondence with SEC
6 Jan 20
UPLOAD
Letter from SEC
5 Jan 20
CT ORDER
Confidential treatment order
17 Dec 18
CT ORDER
Confidential treatment order
11 Jun 18
EFFECT
Notice of effectiveness
11 Jan 18
CORRESP
Correspondence with SEC
9 Jan 18
UPLOAD
Letter from SEC
8 Jan 18
UPLOAD
Letter from SEC
20 Dec 17
CORRESP
Correspondence with SEC
3 Dec 17
Ownership
4
NOVAVAX / James Patrick Kelly ownership change
18 Aug 22
4
NOVAVAX / John Trizzino ownership change
28 Jun 22
4
NOVAVAX / John A Herrmann III ownership change
28 Jun 22
4
NOVAVAX / JAMES F YOUNG ownership change
21 Jun 22
4
NOVAVAX / DAVID M MOTT ownership change
21 Jun 22
4
NOVAVAX / MICHAEL A MCMANUS JR ownership change
21 Jun 22
4
NOVAVAX / MARGARET G MCGLYNN ownership change
21 Jun 22
4
NOVAVAX / Rachel K. King ownership change
21 Jun 22
4
NOVAVAX / RICHARD DOUGLAS ownership change
21 Jun 22
4
NOVAVAX / Gregg H Alton ownership change
21 Jun 22
Patents
Utility
Quil a Fraction with Low Toxicity and Use Thereof
4 Aug 22
Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens.
Utility
Vaccine compositions having improved stability and immunogenicity
21 Jun 22
Disclosed herein are nanoparticles suitable for use in vaccines.
Utility
Methods for Preventing Disease or Disorder Caused by RSV Infection
5 May 22
The present invention is generally related to modified or mutated respiratory syncytial virus (RSV) fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
Utility
Coronavirus Vaccine Formulations
28 Apr 22
Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines.
Utility
Multivalent influenza nanoparticle vaccines
22 Mar 22
Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines.
Transcripts
2022 Q2
Earnings call transcript
9 Aug 22
2022 Q1
Earnings call transcript
10 May 22
2021 Q4
Earnings call transcript
1 Mar 22
2021 Q3
Earnings call transcript
5 Nov 21
2021 Q2
Earnings call transcript
6 Aug 21
2021 Q3
Earnings call transcript
11 May 21
2020 Q4
Earnings call transcript
2 Mar 21
2020 Q3
Earnings call transcript
9 Nov 20
2020 Q2
Earnings call transcript
10 Aug 20
2020 Q1
Earnings call transcript
11 May 20
Reddit threads
My CC's have gone nuclear, looking for advice
16 Aug 22
Veru ready to soar
14 Aug 22
Don’t you really hate when a stock you own goes up a lot then proceeds to go right back down
13 Aug 22
What have been your best/worst trades this past year? (No need to disclose $ amounts)
12 Aug 22
I lost $8000, and recorded the entire thing.
12 Aug 22
(8/11) Thursday's Pre-Market Stock Movers & News
11 Aug 22
My favorite day trading pattern
10 Aug 22
(8/10) Wednesday's Pre-Market Stock Movers & News
10 Aug 22
Sharing experiences on new DT journey so far...so risky....
9 Aug 22
Market timers, this post is for you: the relative cheapness of value stocks is at historic levels, across the world. History suggests to buy.
9 Aug 22